Request Trial
pabradyphoto-2-
pabradyphoto / iStockphoto.com
31 August 2017Americas

FTC orders Baxter to divest rights in Claris deal

The Federal Trade Commission (FTC) has approved a final order combating the anticompetitive effects resulting from Baxter’s proposed $625 million acquisition of Claris’s injectable drugs business.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Court upholds $83m sequencing verdict and sets royalty rate
17 June 2026   A cancer diagnostics company has lost its bid to overturn a jury verdict in a major patent dispute that has also spawned parallel proceedings before the Federal Circuit and PTAB.
Americas
Amgen and subsidiary dealt $20m blow over rodent antibody tech
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.
Americas
Moderna: BioNTech is claiming work ‘it never did’
12 June 2026   In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

More features

UPC hands Occlutech second win against Chinese medtech company in a month
US life sciences damages averaged $33.5m between 2019-2025
Quantum and photonics tech licensing expert joins EIP
Court upholds $83m sequencing verdict and sets royalty rate
Exclusive: ‘Cultural differences are an asset’ at the UPC
Amgen and subsidiary dealt $20m blow over rodent antibody tech
Ex-Simmons head of IP joins Carpmaels & Ransford
Moderna: BioNTech is claiming work ‘it never did’